Assert-IQ vs Eko Foundation Analysis Software with Transformers (EFAST)

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AI Verdict

Assert-IQ is an insertable cardiac monitor providing long-term, continuous arrhythmia detection for chronic management. In contrast, EFAST is a software solution integrated with digital stethoscopes, offering real-time AI analysis for structural murmurs and atrial fibrillation during routine physical examinations. While both aid in cardiac diagnosis, Assert-IQ focuses on extended monitoring, whereas EFAST provides immediate insights at the point of care.

Choose Assert-IQ if…

Choose Assert-IQ if your patient requires long-term, continuous cardiac monitoring (up to 6 years) to diagnose infrequent or asymptomatic arrhythmias that may not be captured during shorter observation periods. This system is ideal for comprehensive arrhythmia detection and remote management, providing proactive alerts and patient-activated symptom logging for a complete diagnostic picture.

View Assert-IQ →

Choose Eko Foundation Analysis Software with Transformers (EFAST) if…

Choose EFAST if you need real-time, AI-powered cardiac insights during routine physical examinations, particularly for immediate detection of structural murmurs and atrial fibrillation. This tool enhances auscultation with advanced audio and waveform visualization, streamlining the diagnostic process directly at the point of care and integrating seamlessly with EMR systems.

View Eko Foundation Analysis Software with Transformers (EFAST) →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Assert-IQ Eko Foundation Analysis Software with Transformers (EFAST)
Pricing Enterprise Subscription-based, contact for details
Deployment Hybrid Cloud-based Software as a Medical Device (SaMD)
FDA Status Cleared AI-estimated 1 AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Eko Foundation Analysis Software with Transformers (EFAST)

EFAST offers a more immediate and interactive user experience for clinicians during routine exams with real-time AI analysis, waveform visualization, and guided exams. Assert-IQ's usability for clinicians primarily involves accessing a cloud platform for data retrieval from an implanted device, with patient interaction via an activator.

Clinical Value

Eko Foundation Analysis Software with Transformers (EFAST)

EFAST provides specific, high-performance metrics for its real-time AI detection of structural murmurs (93% sensitivity, 91% specificity) and AFib (95% sensitivity, 94% specificity), offering immediate, actionable insights during routine exams. Assert-IQ's value lies in its extended, continuous monitoring for intermittent arrhythmias, which serves a different clinical need without providing specific performance metrics in the provided data.

Pricing & Value

Eko Foundation Analysis Software with Transformers (EFAST)

EFAST offers a more transparent and accessible pricing model with a subscription option, a free trial included with stethoscope purchase, and an estimated daily cost for the stethoscope technology. Assert-IQ's enterprise pricing requires direct contact for institutional pricing, suggesting a less transparent and potentially higher barrier to entry.

Enterprise Readiness

Assert-IQ

Assert-IQ, backed by Abbott Medical, explicitly targets large health systems, hospitals, and cardiology clinics, and offers hybrid deployment, indicating robust infrastructure and established support for enterprise-level deployments. While EFAST is also enterprise-ready with EMR integration and cloud deployment, Abbott's scale and long history in complex medical devices provide a stronger foundation for large-scale adoption and support.

Innovation

Eko Foundation Analysis Software with Transformers (EFAST)

EFAST innovates by integrating high-performance AI directly into the routine auscultation process, providing real-time, actionable insights at the point of care, transforming a traditional diagnostic method. Assert-IQ's innovation is in extending the duration (up to 6 years) and sophistication of continuous implantable cardiac monitoring, which is also significant but in a different diagnostic context.

Support & Docs

Tie

Both Abbott Medical and Eko Health are reputable companies expected to provide adequate support and documentation for their medical devices. Without specific comparative data on the quality, breadth, or responsiveness of their support for these particular products, it is not possible to definitively pick a winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Assert-IQ Eko Foundation Analysis Software with Transformers (EFAST)
Name Assert-IQ Eko Foundation Analysis Software with Transformers (EFAST)
Company Abbott Medical Eko Health
Primary Function Long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders. Advanced, FDA-cleared AI model that assists clinicians in identifying structural murmurs associated with heart disease and detecting atrial fibrillation, providing real-time, actionable cardiac insights during routine exams.
Key Detection Focus Advanced arrhythmia detection Structural murmurs and atrial fibrillation (AFib) detection
Monitoring/Analysis Duration Long-term continuous cardiac monitoring (up to 6 years) Real-time AI analysis during auscultation
Mobile App None Not specified

Videos

Demos, reviews, and walkthroughs featuring Assert-IQ and Eko Foundation Analysis Software with Transformers (EFAST).

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Assert-IQ is designed for long-term, continuous monitoring and advanced arrhythmia detection to aid in diagnosing and managing patients with suspected heart rhythm disorders. EFAST assists clinicians in identifying structural murmurs associated with heart disease and detecting atrial fibrillation during routine exams, providing real-time cardiac insights.
Assert-IQ is an insertable cardiac monitor that provides continuous monitoring for up to six years, utilizing advanced arrhythmia detection algorithms. EFAST is an AI model that offers real-time analysis during auscultation with Eko digital stethoscopes for immediate insights.
Assert-IQ focuses on advanced arrhythmia detection, including conditions like atrial fibrillation, bradycardia, tachycardia, and sinus pauses. EFAST specifically detects structural murmurs with 93% sensitivity and 91% specificity, and atrial fibrillation with 95% sensitivity and 94% specificity.
Assert-IQ provides long-term continuous cardiac monitoring data, advanced arrhythmia detection algorithms, proactive clinician alerts, and patient activator for symptom logging. EFAST offers real-time AI analysis during auscultation, enhanced audio with noise cancellation, waveform visualization, guided exams, and secure cloud-based recording and storage of exams.
Assert-IQ has enterprise pricing, requiring contact with Abbott Medical for institutional pricing. EFAST is subscription-based with an Eko+ membership (yearly), and a free trial is included with the purchase of an Eko stethoscope.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.